Cefazolin prophylaxis in obese women undergoing cesarean delivery: a randomized controlled trial.
OBJECTIVE
To compare adipose tissue concentration among obese women receiving 2 g compared with 3 g of precesarean cefazolin prophylaxis.


METHODS
This was a double-blind randomized controlled trial of women with singleton gestations and body mass indexes (BMIs) of 30 or greater at their first prenatal visit undergoing cesarean delivery at term. Women were randomly allocated, stratified by BMI, to receive 2 g or 3 g of cefazolin. Subcutaneous adipose tissue was harvested twice: before (opening) fascial incision and after (closing) fascial closure. The primary outcome was opening adipose tissue cefazolin concentration, measured by high-pressure liquid chromatography.


RESULTS
From April 2013 to July 2014, 58 women were enrolled, 57 included in the analysis: 28 in the 2-g group and 29 in the 3-g group. Baseline characteristics were similar between groups. Median opening adipose tissue concentration was similar between the 2-g and 3-g groups (9.4 [interquartile range 5.1-13.4] compared with 11.7 [interquartile range 7-18.3] micrograms/g, P=.12). The percentage of women with opening concentrations above 8 micrograms/g, the minimally inhibitory concentration of cefazolin for Staphylococcus species, was similar (61% compared with 72%, P=.35). All samples were above 2 micrograms/g, the minimally inhibitory concentration for Enterobacteriaceae. Closing adipose tissue concentrations and stratified analyses were consistent with the overall analysis.


CONCLUSIONS
In obese women undergoing cesarean delivery, prophylaxis with 3 g of cefazolin did not significantly increase adipose tissue concentration. Thus, our data do not support recommendations for 3-g dosing.


METHODS
I.
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, and the Department of Pharmacy, Women and Infants' Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island; and the Center for Anti-infective Research & Development, Hartford Hospital, Hartford, Connecticut.
Lindsay
L
Maggio
David P
DP
Nicolau
Melissa
M
DaCosta
Dwight J
DJ
Rouse
Brenna L
BL
Hughes
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D015992:Body Mass Index; D002437:Cefazolin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002585:Cesarean Section; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D050151:Subcutaneous Fat / Q000378:metabolism*; D013530:Surgical Wound Infection / Q000517:prevention & control*; D055815:Young Adult
D000900:Anti-Bacterial Agents; D002437:Cefazolin